|
|
There is a correlation between LTG serum level and tolerability, independent of the use of other AEDs. Adverse effects requiring a dose change are uncommon with the most frequently encountered LTG concentrations (<10 ?g/ml) and occur in only 7.4% of patients at levels obtained during the majority of clinical trials (<5 ?g/mL). An initial target range of 1.5 to 10 ?g/mL is suggested, though higher levels, up to >20 ?g/mL, are often tolerated and can lead to additional efficacy in refractorypatients. |
|